Hormonal
GLP-1 receptor agonists (specifically liraglutide, subcutaneous semaglutide, and dulaglutide) significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes, independent of glucose-lowering effects.
If you have Type 2 Diabetes and established heart disease or high risk, ask your doctor about GLP-1 receptor agonists like liraglutide, semaglutide, or dulaglutide. These drugs are proven to significantly lower your risk of heart attack, stroke, and cardiovascular death, regardless of how well they control your blood sugar. They are now a standard recommendation in guidelines for high-risk patients.
Multiple large cardiovascular outcome trials with novel glucose-lowering agents, namely SGLT2i (SGLT2 inhibitors) and GLP-1 RA (GLP-1 receptor agonists), have demonstrated robust and significant reductions of major adverse cardiovascular events (MACE)... These beneficial effects on cardiovascular outcomes are thought to be largely independent of the glucose-lowering properties of these agents.
Why this rating
Based on multiple large, randomized, placebo-controlled cardiovascular outcome trials (CVOTs) and meta-analyses.
Source
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Nikolaus Marx et al. · Circulation · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →